Systemic inflammation induces endothelial dysfunction in peritoneal dialysis patients

Vascular Disease Prevention

Volumn 4, Issue 3, 2007, Pages 217-224

  Aguilera, Abelardo ^b   Velásquez, Eddy ^a   Bajo, María A ^b   Ruiz Caravaca, Maria L ^c   Pavone, Mario ^b   Martínez, Victoria ^d   Del Peso, Gloria ^b   Herranz, Angel ^c   Cuesta, Maria V ^c   López Cabrera, Manuel ^b   Selgas, Rafael ^b  

^a Hospital de Monteprincipe   (Spain)

^b HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^c HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^d Hospital Universitario de la Princesa ^*

Author keywords

Cardiovascular risk; Endothelial dysfunction; MIA syndrome; Peritoneal dialysis; Systemic inflammation

Indexed keywords

C REACTIVE PROTEIN; FIBRINOGEN; HOMOCYSTEINE; LIPOPROTEIN A; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR; PLATELET DERIVED GROWTH FACTOR; THROMBOMODULIN; TISSUE PLASMINOGEN ACTIVATOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST; ENDOTHELIAL DYSFUNCTION; FEMALE; FOLLOW UP; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MALE; NUTRITIONAL ASSESSMENT; PERITONEAL DIALYSIS; PRIORITY JOURNAL; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UPPER RESPIRATORY TRACT INFECTION; VEIN OCCLUSION;

EID: 34547798553     PISSN: 15672700     EISSN: None     Source Type: Journal    
DOI: 10.2174/156727007781387975     Document Type: Article

References (35)

1. Schächinger V, Zeiher AM. Atherosclerosis-recent insights into basic mechanisms and their clinical impact. Nephrol Dial Transplant 2002; 17: 2055-2064.
2. Kim SB, Yang WS, Park JS. Role of hypoalbuminemia in the genesis of cardiovascular disease in dialysis patients. Perit Dial Int 1999; 19 (S2): S144-S149.
3. Nakayama M, Yamada K, Yamanoto Y, et al. Vascular endothelial dysfunction in patients on regular dialysis. Clin Nephrol 1994; 42: 117-120.
4. Culleton BF, Wilson PW. Thrombogenic risk factors for cardiovascular disease in dialysis patients. Sem Dial 1999; 12: 117-125.
5. Stenvinkel P, Heimbürger O, Lindholm B, Kaysen G, Bersgtröm J. Are there two types of malnutrition in chronic renal failure? Evidence for relationship between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol Dial Transplant 2000; 15: 953-960.
6. Stenvinkel P. Endothelial dysfunction and inflammation-is there link. Nephrol Dial Transplant 2001; 16: 1968-1971.
7. Ross R. Atherosclerosis and inflammatory disease. N Engl J Med 1999; 340: 115-126.
8. Aguilera A, Selgas R, Ruíz-Caravaca ML, et al. Effects of recombinant human erythropoietin on functional and injury endothelial markers in peritoneal dialysis patients. Perit Dial Int 1999; 19 (S2): S161-S166.
9. Oshima T, Ozono R, Yano Y, et al. Association of Helicobacter pylori infection with systemic inflammation and endothelial dysfunction in healthy male subjects. J Am Coll Cardiol 2005; 45: 1219-1222.
10. Vlachopoulos C, Dima I, Aznaouridis K, et al. Acute systemic inflammation increases arterial stiffness and decreases wave reflections in healthy individuals. Circulation 2005; 112: 2193-2200.
11. Selgas R, Fernández-Reyes MJ, Bosque E, et al. Functional longevity of the human peritoneum: How long is Continuous Ambulatory Peritoneal Dialysis possible? Results of a prospective medium-long-term study. Am J Kidney Dis 1994; 23: 64-73.
12. Aguilera A, Codoceo R, Selgas R, et al. Anorexigen (TNF-alpha, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients: their relationship with nutritional parameters. Nephrol Dial Transplant 1998; 13:1476-1483.
13. Amore A, Coppo R. Immunological basis of inflammation in dialysis. Nephrol Dial Transplant 2002; 17 (S8): S16-S24.
14. Zalewski D, Shi Y, Nardone D, et al. Evidence for reduced fibrinolytic activity in unstable angina at rest. Clinical biochemical and angiographic correlation. Circulation 1991; 83: 1685-1691.
15. Schleef RR, Bevilacqua MP, Sadwey M, Gimbrone MA, Loskutoff DJ. Cytokine activation of the vascular endothelial effect on tissue-type plasminogen activator and type-1 plasminogen activator inhibitor. J Biol Chem 1988; 263: 5797-5803.
16. Chia S, Ludlam CA, Fox KA, Newby DE. Acute systemic inflammation enhances endothelium-depend tissue plasminogen activator release in men. J Am Coll Cardiol 2003; 15: 333-339.
17. Esmon CT. Does inflammation contribute to thrombotic events? Haemostasis 2000; 30 (S2): S34-S40.
18. Hamsten A, De Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
19. Tomura S, Nakamura Y, Deguchi F, et al. Plasma von Willebrand factor and thrombomodulin as marker of vascular disorders in patients undergoing regular hemodialysis therapy. Thromb Res 1990; 58: 413-417.
20. Tannenbaum SH, Gralnick HR. Gamma interferon modulate von Willebrand factor release by cultured human endothelial cells. Blood 1990; 75: 2177-2184.
21. Moncada S, Palmer RM, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142.
22. Egashira K, Inou T, Hirooka Y, et al. Evidence of impaired endothelium-dependent coronary vasodilatation in patients with angina pectoris and normal coronary angiograms. N Engl J Med 1993; 328: 1659-1664.
23. Wang P, Ba ZF, Chaudry IH. Administration of tumor necrosis factor-alpha in vivo depress endothelial dependent-relaxation. Am J Physiol 1994; 266: H2535-2541.
24. Yoshizumi M, Perreila MA, Burnett JC, Lee ME. Tumor necrosis factor downregulate an endothelial nitric oxide synthase mRNA by shortening its half-live. Circ Res 1993; 73: 205-209.
25. Wang XL, Liu SX, Wilcken DE. Circulating transforming growth factor beta 1 and coronary disease. Cardiovasc Res 1997; 34: 404-410.
26. Stefoni S, Cianciolo G, Donati G, et al. Low TGF-beta1 serum levels are a risk factor for atherosclerosis disease in ESRD patients. Kidney Int 2002; 61: 324-335.
27. Macfelda K, Weiss TW, Kaun C, et al. Plasminogen activator inhibitor 1 expression is regulated by inflammatory mediators interleukin-1 alpha, tumor necrosis factor-alpha, transformin growth factor-beta and oncostatin in human cardiac myocytes. J Mol Cell Cardiol 2002; 34: 1681-1691.
28. Elenkov IJ, Chrousos GP. Stress hormones, proinflammatory and anti-inflammatory cytokines autoimmunity. Ann NY Acad Sci 2002; 966: 290-303.
29. Kronenberg F. Homocysteine, lipoprotein (a) and fibrinogen: metabolic risk factors for cardiovascular complications of chronic renal failure. Curr Opin Nephrol Hypertens 1998; 7: 271-278.
30. Kario K, Matsu T, Kobayashi H, Matsu M, Asada R, Oide M. High lipoprotein (a) levels in chronic hemodialysis patients are closely related to the acute phase reaction. Thromb Hemost 1995; 74: 1020-1024.
31. Harper PC, Hermann A, Zhang X, Ostfeld I, Borth W. Lipoprotein(a), plasmin modulation, and atherosclerosis. Thromb Haemat 1995; 74: 382-386.
32. Djurovic S, Thelle DS, Ringstad J, Christensen B, Berg K. Altered serum concentration of TGF-beta 1 and Lp(a) lipoprotein their correlation in patients with first acute myocardial infarction. Nutr Metab Cardiovasc Dis 1999; 9: 250-254.
33. Nishio E, Watanabe Y. Homocysteine as a modulator of platelet-derived growth factor action in vascular muscle cells: a possible role for hyperoxide. Br J Pharmacol 1997; 122: 269-274.
34. Pecoit-Filho R, Heimbürger O, Barany P, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis 2003; 41: 1212-1218.
35. Aguilera A, Codoceo R, Bajo MA, et al. Helicobacter pylori infection: a new cause of anorexia in peritoneal dialysis patients. Perit Dial Int 2001; 21(S3): S152-S156.